Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.

[1]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[2]  I. Frazer.  Interaction of human papillomaviruses with the host immune system: a well evolved relationship. , 2009, Virology.

[3]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[4]  L. Nasir,et al.  Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. , 2008, Veterinary dermatology.

[5]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[6]  D. Lowy,et al.  Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of Inhibition , 2007, Journal of Virology.

[7]  C. Wheeler,et al.  Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial , 2007 .

[8]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[9]  D. Lowy,et al.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. , 2005, Virology.

[10]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[11]  D. Lowy,et al.  Generation of HPV pseudovirions using transfection and their use in neutralization assays. , 2005, Methods in molecular medicine.

[12]  E. Kriehuber,et al.  Different Heparan Sulfate Proteoglycans Serve asCellular Receptors for HumanPapillomaviruses , 2003, Journal of Virology.

[13]  N. Christensen,et al.  Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein , 2002, Journal of Virology.

[14]  D. Lowy,et al.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope , 1997, Journal of virology.

[15]  M. Campo.  Vaccination against papillomavirus in cattle. , 1997, Clinics in dermatology.

[16]  D. Lowy,et al.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype , 1996, Journal of virology.

[17]  D. Lowy,et al.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. , 1996, Virology.

[18]  A. B. Jenson,et al.  Antigenicity of bovine papillomavirus type 1 (BPV-1) L1 virus-like particles compared with that of intact BPV-1 virions. , 1996, The Journal of general virology.

[19]  R. Schlegel,et al.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Lowy,et al.  Divergent human papillomavirus type 16 variants are serologically cross-reactive. , 1995, The Journal of infectious diseases.

[21]  D. Lowy,et al.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection , 1995, Journal of virology.

[22]  Darren W. Henderson,et al.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins , 1994, Journal of virology.

[23]  D. Lowy,et al.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. , 1994, Journal of the National Cancer Institute.

[24]  M. Campo,et al.  Latent papillomavirus infection in cattle. , 1994, Research in veterinary science.

[25]  N. Christensen,et al.  Monoclonal antibody neutralization of BPV-1. , 1993, Virus research.

[26]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Lowy,et al.  A quantitative in vitro focus assay for bovine papilloma virus. , 1980, Virology.